AI Article Synopsis

  • The study focused on evaluating the consistency and reliability of hepatic venous pressure gradient (HVPG) measurements in patients with cirrhosis, specifically for randomized controlled trials (RCTs) addressing portal hypertension (PH).
  • Analysis of 20 RCTs revealed that variability in HVPG measurements was lower in trials with only compensated cirrhosis patients, leading to smaller sample size requirements for these studies compared to those with decompensated cirrhosis.
  • Findings indicate that while HVPG measurement is reliable, the variability is greater in populations with more severe liver disease, which is crucial for planning clinical trials and using HVPG to direct treatment strategies.

Article Abstract

Background And Aims: Portal hypertension (PH) is a major driver for cirrhosis complications. Portal pressure is estimated in practice by the HVPG. The assessment of HVPG changes has been used for drug development in PH. This study aimed at quantifying the test-retest reliability and consistency of HVPG in the specific context of randomized controlled trials (RCTs) for the treatment of PH in cirrhosis and its impact on power calculations for trial design.

Approach And Results: We conducted a search of published RCTs in patients with cirrhosis reporting individual patient-level data of HVPG at baseline and after an intervention, which included a placebo or an untreated control arm. Baseline and follow-up HVPGs in the control groups were extracted after digitizing the plots. We assessed reliability and consistency and the potential impact of study characteristics. We retrieved a total of 289 before and after HVPG measurements in the placebo/untreated groups from 20 RCTs. The time span between the two HVPG measurements ranged between 20 minutes and 730 days. Pre-/post-HVPG variability was lower in studies including only compensated patients; therefore, modeled sample size calculations for trials in compensated cirrhosis were lower than for decompensated cirrhosis. A higher proportion of alcohol-associated cirrhosis and unicentric trials was associated with lower differences between baseline and follow-up measurements. The smallest detectable difference in an individual was 26% and 30% in compensated and decompensated patients, respectively.

Conclusions: The test-retest reliability of HVPG is overall excellent. Within-individual variance was higher in studies including higher proportions of decompensated patients. These findings should be taken into account when performing power analysis for trials based on the effects on HVPG or when considering HVPG as a tool to guide therapy of PH.

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.32033DOI Listing

Publication Analysis

Top Keywords

test-retest reliability
12
reliability consistency
12
hvpg
10
consistency hvpg
8
randomized controlled
8
controlled trials
8
baseline follow-up
8
hvpg measurements
8
studies including
8
decompensated patients
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!